EA
EDIT icon

Edge Advisors’s Editas Medicine EDIT Stock Holding History

Edge Advisors’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		$35K Buy
+1,000
New +$35.4K ﹤0.01% 560

Other funds holding EDIT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Edge Advisors's EDIT Position: Q2 2018 in Review

Edge Advisors opened a new position in Editas Medicine (EDIT) in Q2 2018: 1,000 shares worth $35K. The stake represents ﹤0.01% of the portfolio and ranks #560 among its holdings.

215 funds tracked by Wall St. Rank hold EDIT as of Q2 2018.

  • Edge Advisors held 1,000 shares of Editas Medicine worth $35K as of Q2 2018.
  • Editas Medicine was a new Edge Advisors position in Q2 2018.
  • Editas Medicine made up ﹤0.01% of Edge Advisors's portfolio in Q2 2018, its #560 holding.
  • 215 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2018.

Based on Edge Advisors's 13F filing for Q2 2018, filed 14 Aug 2018.